Canada House's Wholly-Owned Subsidiary, Abba Medix Inc., Obtains License to Cultivate Medical Cannabis

TORONTO, ONTARIO--(Marketwired - Sept. 1, 2017) - Canada House Wellness Group Inc. (CSE:CHV)(CSE:CHV.CN)(CNSX:CHV) ("Canada House" or the "Company") is pleased to announce that its wholly-owned subsidiary, Abba Medix Inc., has been granted by Health Canada a license to cultivate cannabis, pursuant to the Access to Cannabis for Medical Purposes Regulations "ACMPR".

"We are very pleased to have received a license to cultivate cannabis under Canada's ACMPR," commented Company Director Riley McGee. "Our team understands that a license to cultivate is just the beginning of what's to come for Abba Medix, which looks to become a recognized producer of the highest quality of cannabis products within its Pickering, Ontario indoor grow facility."

Canada House Wellness Group Inc.

Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company's goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit http://www.canadahouse.ca. or www.sedar.com

Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute "forward‐looking statements", within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are "forward‐looking statements". Such "forward‐looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company's public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.